Skip to main content

Cost-efficient European adaptations of global health economic models

Experience with model adaptations in Austria, Belgium, France, Germany, Italy, Norway, Netherlands, Spain, Sweden, the UK

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

Extended reimbursement for next-generation sequencing (NGS) in Belgium

24 Jul 2023

Molecular biology tests by next-generation sequencing (NGS) in oncology and hemato-oncology are temporarily reimbursed as a pilot under a specific agreement (Convention) with the National Institute for Health and Disability Insurance (INAMI-RIZIV) from 2019.

On July 1, 2023, the Convention was extended for one year. The lists with eligible clinical indications connected to specific biomarkers (separately for solid and hematological tumors) were updated as well.

See more information in French here and in Dutch here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Contact us to get a free, three-month, no-obligation trial.